News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,845 Results
Type
Article (39693)
Company Profile (247)
Press Release (658905)
Multimedia
Podcasts (49)
Webinars (12)
Section
Business (204169)
Career Advice (2007)
Deals (35418)
Drug Delivery (95)
Drug Development (81044)
Employer Resources (172)
FDA (16180)
Job Trends (14858)
News (345187)
Policy (32538)
Tag
Academia (2554)
Accelerated approval (5)
Adcomms (20)
Allergies (85)
Alliances (49433)
ALS (88)
Alzheimer's disease (1378)
Antibody-drug conjugate (ADC) (124)
Approvals (16185)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (175)
Bladder cancer (78)
Brain cancer (27)
Breast cancer (278)
Cancer (2258)
Cardiovascular disease (174)
Career advice (1676)
Career pathing (30)
CAR-T (151)
Cell therapy (423)
Cervical cancer (19)
Clinical research (65986)
Collaboration (832)
Company closure (1)
Compensation (533)
Complete response letters (19)
COVID-19 (2588)
CRISPR (40)
C-suite (241)
Cystic fibrosis (100)
Data (2205)
Decentralized trials (2)
Denatured (18)
Depression (43)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (99)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86637)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112411)
Executive appointments (722)
FDA (17443)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (748)
Gene editing (104)
Generative AI (19)
Gene therapy (302)
GLP-1 (709)
Government (4416)
Grass and pollen (4)
Guidances (67)
Healthcare (18814)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (115)
Indications (29)
Infectious disease (2730)
Inflammatory bowel disease (137)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (96)
Interviews (311)
IPO (16508)
IRA (40)
Job creations (3630)
Job search strategy (1422)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7909)
Liver cancer (75)
Lung cancer (320)
Lymphoma (154)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (67)
Medical device (13377)
Medtech (13382)
Mergers & acquisitions (19455)
Metabolic disorders (685)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (88)
Neuropsychiatric disorders (27)
Neuroscience (1913)
NextGen: Class of 2025 (6512)
Non-profit (4480)
Now hiring (39)
Obesity (364)
Opinion (204)
Ovarian cancer (75)
Pain (87)
Pancreatic cancer (83)
Parkinson's disease (148)
Partnered (21)
Patents (233)
Patient recruitment (112)
Peanut (46)
People (57301)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20557)
Phase II (29056)
Phase III (21649)
Pipeline (1203)
Policy (139)
Postmarket research (2563)
Preclinical (8738)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (378)
Real estate (5907)
Recruiting (65)
Regulatory (22282)
Reports (46)
Research institute (2320)
Resumes & cover letters (349)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (69)
Series A (130)
Series B (84)
Service/supplier (11)
Sickle cell disease (52)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3576)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (40)
The Weekly (29)
Vaccines (689)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (11)
Last 7 days (897)
Last 30 days (2522)
Last 365 days (32624)
2025 (10736)
2024 (35218)
2023 (40076)
2022 (51173)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31481)
2015 (37552)
2014 (31319)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (718)
Alabama (53)
Alaska (7)
Arizona (232)
Arkansas (13)
Asia (37840)
Australia (6185)
California (6134)
Canada (2017)
China (523)
Colorado (266)
Connecticut (274)
Delaware (148)
Europe (81247)
Florida (912)
Georgia (206)
Idaho (57)
Illinois (536)
India (25)
Indiana (308)
Iowa (11)
Japan (162)
Kansas (104)
Kentucky (24)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4568)
Michigan (220)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1727)
New Mexico (28)
New York (1746)
North Carolina (967)
North Dakota (8)
Northern California (2682)
Ohio (204)
Oklahoma (14)
Oregon (34)
Pennsylvania (1377)
Puerto Rico (12)
Rhode Island (33)
South America (1096)
South Carolina (23)
South Dakota (1)
Southern California (2303)
Tennessee (101)
Texas (907)
United States (23126)
Utah (180)
Virginia (146)
Washington D.C. (62)
Washington State (551)
West Virginia (3)
Wisconsin (54)
698,845 Results for "nephros inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
April 15, 2025
·
1 min read
Business
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.
March 7, 2024
·
12 min read
Press Releases
Nephros Schedules Third Quarter 2024 Financial Results Conference Call
November 1, 2024
·
1 min read
Press Releases
Nephros Announces Financial Results for Quarter Ended September 30, 2024
November 8, 2024
·
10 min read
Press Releases
Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC
December 4, 2024
·
1 min read
Business
Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results
Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will file its fourth quarter and fiscal year financial results on Thursday March 7, 2024 after market close and will host a conference call that same day at 4:30pm ET.
February 29, 2024
·
1 min read
Business
Nephros Announces Results for Quarter Ended September 30, 2023
Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2023.
November 8, 2023
·
11 min read
Drug Development
Rege Nephro CO., Ltd. Announces Patient Enrollment for Phase II Clinical Trial of Tamibarotene for ADPKD
Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.
May 28, 2024
·
2 min read
Business
Nephros Announces Financial Results for Quarter Ended June 30, 2024
August 8, 2024
·
9 min read
Press Releases
Nephros Schedules Second Quarter 2024 Financial Results Conference Call
August 1, 2024
·
1 min read
1 of 69,885
Next
